|  | 0–6 m participant characteristics (models 1a-3) |
---|---|---|
n (% full cohort) | Â | 242 (41%) |
Arm, n (% sample) | Â | Â |
 | Usual care | 16 (7%) |
 | Diet | 115 (48%) |
 | Diet and exercise | 111 (46%) |
Male, n (%) | Â | 163 (67%) |
White ethnicity, n (%) | Â | 236 (98%) |
Smoker at baseline, n (%) | Â | 17 (7%) |
Age, years | Â | 62 (57, 69) |
Time since diagnosis, years | Â | 0.5 (0.4, 0.6) |
IMD score | Â | 12.6 (6.4, 18.9) |
Total activity, counts/min | Â | 291 (226, 363) |
Total activity change 0–6 m, counts/min |  | 16 (− 44, 91) |
MVPA, mins/day | Â | 21 (13, 36) |
MVPA change 0–6 m, mins/day |  | 3 (− 6, 18) |
Weight, kg | Â | 86.5 (77.1, 94.0) |
Weight change 0–6 m, kg |  | − 2.1 (− 3.9, − 0.1) |
BMI, kg/m2 | Â | 29.5 (27.3, 32.7) |
BMI change 0–6 m, kg/m2 |  | − 0.7 (− 1.4, 0.0) |
HbA1c, mmol/mol | Â | 47 (43, 54) |
HbA1c, % | Â | 6.5 (6.1, 7.1) |
HbA1c change 0–6 m, mmol/mol |  | − 2.2 (− 5.5, 3.3) |
HbA1c change 0–6 m, % |  | − 0.2 (− 0.5, 0.3) |
OHA prescription, n (%) | Â | Â |
 | Metformin | 85 (35%) |
 | Sulphonylurea | 22 (9%) |
 | Glitazone | 2 (1%) |
Baseline under-reporters, n (%) | Â | 142 (56%) |